{"entity":{"type":"insider","cik":"0001282889","url":"/insider/0001282889","json_url":"/insider/0001282889.json","name":"ACMP IV LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":4,"n_filings":4,"first":"2011-02-18","last":"2015-04-14","span_basis":"filed_date"},"name_variants":[{"name":"ACMP IV LLC","source":"filing","n_filings":4,"first_seen":"2011-02-18","last_seen":"2015-04-14"}],"transactions":[{"id":8248760,"accession":"0001209191-15-034053","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-15-034053","line_url":"/filing/0001209191-15-034053#line-5","is_derivative":false,"issuer_cik":"0001198325","issuer_name":"Carbylan Therapeutics, Inc.","issuer_ticker":"CBYL","issuer_name_source":null,"issuer_url":"/issuer/0001198325","owner_cik":null,"owner_name":"JANNEY DANIEL; ACMP IV LLC; ACP IV, L.P.","owner_display_name":"JANNEY DANIEL","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":877500.0,"shares_display":"877,500","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":4387500.0,"total_display":"4,387,500.00","total_whole":"4,387,500","shares_owned_after":4343550.0,"shares_owned_after_display":"4,343,550","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-04-14","filed_date":"2015-04-14","scope":"insider"},{"id":6704535,"accession":"0001209191-14-036963","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-036963","line_url":"/filing/0001209191-14-036963#line-1","is_derivative":false,"issuer_cik":"0001198325","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001198325","owner_cik":null,"owner_name":"JANNEY DANIEL; NOHRA GUY P; ACMP IV LLC; ACP IV, L.P.","owner_display_name":"JANNEY DANIEL","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300000.0,"shares_display":"300,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4800000.0,"total_display":"4,800,000.00","total_whole":"4,800,000","shares_owned_after":3616099.0,"shares_owned_after_display":"3,616,099","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-05-22","filed_date":"2014-05-27","scope":"insider"},{"id":5338643,"accession":"0001209191-13-050246","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-13-050246","line_url":"/filing/0001209191-13-050246#line-5","is_derivative":false,"issuer_cik":"0001198325","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001198325","owner_cik":null,"owner_name":"NOHRA GUY P; JANNEY DANIEL; ACMP IV LLC; ACP IV, L.P.","owner_display_name":"NOHRA GUY P","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":110000.0,"shares_display":"110,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":1100000.0,"total_display":"1,100,000.00","total_whole":"1,100,000","shares_owned_after":3916099.0,"shares_owned_after_display":"3,916,099","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-10-30","filed_date":"2013-11-01","scope":"insider"},{"id":9142290,"accession":"0001209191-11-011322","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-11-011322","line_url":"/filing/0001209191-11-011322#line-6","is_derivative":false,"issuer_cik":"0001198323","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001198323","owner_cik":null,"owner_name":"JANNEY DANIEL; ACP IV, L.P.; NOHRA GUY P; ACMP IV LLC; DELEAGE JEAN; Mack David Henry","owner_display_name":"JANNEY DANIEL","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":680000.0,"shares_display":"680,000","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":3400000.0,"total_display":"3,400,000.00","total_whole":"3,400,000","shares_owned_after":2794907.0,"shares_owned_after_display":"2,794,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-02-16","filed_date":"2011-02-18","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001348911","name":"Carbylan Therapeutics, Inc.","url":"/issuer/0001348911","role":"Ten percent owner","n_filings":1,"first_seen":"2015-04-14","last_seen":"2015-04-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001337553","name":"AERIE PHARMACEUTICALS INC","url":"/issuer/0001337553","role":"Ten percent owner","n_filings":2,"first_seen":"2013-11-01","last_seen":"2014-05-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001427925","name":"ACELRX PHARMACEUTICALS INC","url":"/issuer/0001427925","role":"Ten percent owner","n_filings":1,"first_seen":"2011-02-18","last_seen":"2011-02-18"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001282889","retrieved_at":"2026-08-22T12:50:11+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}